A few other tidbits: Briefing book is complete
Post# of 157793
(Total Views: 585)
Posted On: 08/21/2025 12:37:17 AM
A few other tidbits:
Briefing book is complete and ready to present to the FDA.
90% of patients had PDL1 induction.
submitting a rollover protocol for CRC patients and will provide a Checkpoint Inhibitor (CI)
submitting a phase II follow-up protocol to FDA for TNBC (still fast tracked designated)
submitting a compassionate use protocol for TNBC patients that don't meet eligibility for the phase II above
Leronlimab transfers to brain via T-cells
don't know the site of action for PD1 inhibitors in the brain or in the periphery.
KOL and investigator initiated study in Glioblastoma, give Leronlimab to recurring Glioblastoma patients before surgery (disrupt the microenvironment), measure PD1 induction, and offer a checkpoint inhibitor and hope the activity is in the periphery. The activated cells can then enter the brain and attack the cancer.
Abstracts: AACR Conference (details on PDL story)
San Antonio Breast Cancer Symposium (update on patients with TNBC.
ASCO next summer (sharing 5 year survival).
LATCH protocol to be submitted very soon.
Preclinical work ongoing for stroke.
Will continue to accept via EIND program, pancreatic, sarcoma, prostrate, and urothelial cancer patients.
Heading to open waters. Dive! Dive! Dive!
Briefing book is complete and ready to present to the FDA.
90% of patients had PDL1 induction.
submitting a rollover protocol for CRC patients and will provide a Checkpoint Inhibitor (CI)
submitting a phase II follow-up protocol to FDA for TNBC (still fast tracked designated)
submitting a compassionate use protocol for TNBC patients that don't meet eligibility for the phase II above
Leronlimab transfers to brain via T-cells
don't know the site of action for PD1 inhibitors in the brain or in the periphery.
KOL and investigator initiated study in Glioblastoma, give Leronlimab to recurring Glioblastoma patients before surgery (disrupt the microenvironment), measure PD1 induction, and offer a checkpoint inhibitor and hope the activity is in the periphery. The activated cells can then enter the brain and attack the cancer.
Abstracts: AACR Conference (details on PDL story)
San Antonio Breast Cancer Symposium (update on patients with TNBC.
ASCO next summer (sharing 5 year survival).
LATCH protocol to be submitted very soon.
Preclinical work ongoing for stroke.
Will continue to accept via EIND program, pancreatic, sarcoma, prostrate, and urothelial cancer patients.
Heading to open waters. Dive! Dive! Dive!
(18)
(0)